tiprankstipranks
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
PremiumPress ReleasesGracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
3M ago
Gracell announces FDA clearance of IND application for Phase 1 trial of GC012F
PremiumThe Fly
Gracell announces FDA clearance of IND application for Phase 1 trial of GC012F
3M ago
FDA instructs drugmakers to add T cell malignancy risk info to CAR-T labels
PremiumThe Fly
FDA instructs drugmakers to add T cell malignancy risk info to CAR-T labels
3M ago
Gracell downgraded to Hold from Buy at Jefferies
PremiumThe FlyGracell downgraded to Hold from Buy at Jefferies
4M ago
Gracell downgraded to Neutral from Buy at BTIG
PremiumThe Fly
Gracell downgraded to Neutral from Buy at BTIG
4M ago
Gracell downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Gracell downgraded to Neutral from Buy at H.C. Wainwright
4M ago
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
PremiumPress ReleasesGracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
4M ago
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
PremiumPress Releases
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
4M ago
Gracell announces China NMPA clearance of IND application for trial of GC012F
PremiumThe Fly
Gracell announces China NMPA clearance of IND application for trial of GC012F
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100